Singapore

The Health Sciences Authority (HSA) is the primary regulatory authority for health products in Singapore, operating under the Ministry of Health (MOH). The main governing legislation includes the Health Products Act (HPA) and its associated regulations, which cover medical devices, therapeutic products (pharmaceuticals and biologics), health supplements, cosmetics, and in-vitro diagnostics. The HSA administers distinct regulatory pathways depending on product class and type: therapeutic products are reviewed under the Therapeutic Products (TP) regulatory framework, while medical devices are registered under the Medical Devices (MD) framework. Approval routes include the full evaluation route, the abridged route (leveraging prior approvals from reference agencies such as the US FDA, EMA, TGA, or Health Canada), and the verification route for products already approved by at least two HSA-recognized reference agencies. These tiered pathways allow review timelines to range from approximately 30 days for verification route submissions to up to 270 days or more for full evaluation dossiers.

All applicants seeking product registration in Singapore must submit dossiers through HSA's online PRISM (Product Registration Informatics System Management) platform. Singapore accepts submissions aligned with the Common Technical Document (CTD) format and the ASEAN Common Technical Dossier (ACTD) format, consistent with its commitments under the ASEAN Harmonization framework. A local Singaporean-registered company must serve as the product registrant and regulatory correspondent, acting as the liaison with HSA. Singapore has been an active adopter of regulatory convergence initiatives, including participation in Project Orbis for oncology products and the Access Consortium for collaborative reviews. Recent reforms have focused on strengthening the post-market surveillance framework, expanding the regulatory scope of digital health tools and Software as a Medical Device (SaMD) under an updated classification system, and streamlining pathways for innovative and combination products.

Public sector procurement of health products in Singapore is highly centralized and professionally managed. The Ministry of Health (MOH) oversees national health policy and funding, while procurement operations for the public health cluster are coordinated through the Healthtech Office and the public healthcare institutions grouped into two major integrated clusters: the National University Health System (NUHS), the National Healthcare Group (NHG), and the Singapore Health Services (SingHealth). Large-scale procurement for public hospitals and polyclinics is typically conducted through centralized group tenders managed by the respective cluster procurement offices or through the Ministry of Finance's Government Procurement framework, which mandates adherence to the Government Procurement Act and aligns with World Trade Organization Government Procurement Agreement (WTO GPA) obligations. The Health Sciences Authority also plays a role in facilitating procurement through its product registration requirements, as only registered products may be supplied to public institutions. The government has increasingly leveraged value-based procurement principles, assessing total cost of care rather than unit price alone, and the Agency for Care Effectiveness (ACE) conducts health technology assessments (HTAs) to inform formulary and reimbursement decisions under the national drug and device formularies.

Singapore's private sector is substantial and represents a significant proportion of total healthcare expenditure, with private hospitals, specialist outpatient clinics, and general practitioner networks procuring health products independently through authorized local distributors and importers. Procurement in the private sector is commercially driven and governed by market dynamics, with no mandated national tender process. Singapore does not have a significant presence of donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country and does not qualify for such mechanisms as a recipient. However, Singapore-based companies and regional health entities may engage with these channels for procurement destined for other markets in the Asia-Pacific region. There is no formal local manufacturing preference policy embedded in public procurement rules, though the Singapore Economic Development Board (EDB) and Enterprise Singapore actively encourage pharmaceutical and medtech manufacturing investment through incentive schemes, and national resilience considerations following the COVID-19 pandemic have prompted greater strategic interest in local and regional supply chain diversification.